CRGX vs. PTGX, VERA, CGON, BEAM, MIRM, HRMY, CNTA, IDYA, MESO, and AGIO
Should you be buying CARGO Therapeutics stock or one of its competitors? The main competitors of CARGO Therapeutics include Protagonist Therapeutics (PTGX), Vera Therapeutics (VERA), CG Oncology (CGON), Beam Therapeutics (BEAM), Mirum Pharmaceuticals (MIRM), Harmony Biosciences (HRMY), Centessa Pharmaceuticals (CNTA), IDEAYA Biosciences (IDYA), Mesoblast (MESO), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry.
CARGO Therapeutics vs.
CARGO Therapeutics (NASDAQ:CRGX) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends.
CARGO Therapeutics currently has a consensus target price of $31.80, suggesting a potential upside of 156.66%. Protagonist Therapeutics has a consensus target price of $53.78, suggesting a potential upside of 46.06%. Given CARGO Therapeutics' higher possible upside, research analysts clearly believe CARGO Therapeutics is more favorable than Protagonist Therapeutics.
CARGO Therapeutics has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.
In the previous week, CARGO Therapeutics had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for CARGO Therapeutics and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.59 beat CARGO Therapeutics' score of 0.55 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Protagonist Therapeutics has higher revenue and earnings than CARGO Therapeutics. CARGO Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
93.2% of CARGO Therapeutics shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 1.4% of CARGO Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Protagonist Therapeutics received 264 more outperform votes than CARGO Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CARGO Therapeutics an outperform vote while only 60.83% of users gave Protagonist Therapeutics an outperform vote.
Protagonist Therapeutics has a net margin of 52.76% compared to CARGO Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 34.68% beat CARGO Therapeutics' return on equity.
Summary
Protagonist Therapeutics beats CARGO Therapeutics on 13 of the 17 factors compared between the two stocks.
Get CARGO Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CARGO Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRGX) was last updated on 1/20/2025 by MarketBeat.com Staff
